175
Views
28
CrossRef citations to date
0
Altmetric
Review

The dose of inhaled corticosteroids in patients with COPD: when less is better

&
Pages 3539-3547 | Published online: 25 Oct 2018

Figures & data

Figure 1 Incidence rates of pneumonia in different studies according to doses of ICS.

Notes: *Comparison between beclometasone/formoterol 640/18 µg formoterol 18 µg. Comparison between fluticasone furoate/umeclidinium/vilanterol vs umeclidinium/vilanterol. Comparison between FF/vilanterol vs umeclidinium/vilanterol. §Comparison between beclometasone/formoterol 320/18 µg formoterol 18 µg. Both arms of the study were treated with ICS (extrafine BDP/FF/G 400/24/50 vs extrafine BDP/FF 400/24). Only ICS doses approved in COPD are considered.
Abbreviations: BDP, beclomethasone dipropionate; FF, fluticasone furoate; G, glycopyrronium; ICS, inhaled corticosteroids.
Figure 1 Incidence rates of pneumonia in different studies according to doses of ICS.

Table 1 Characteristics and results of major long-term Phase III double-blind, randomized controlled clinical trials with ICS in patients with COPD

Figure 2 The dose-response curve of ICS.

Note: Reproduced from Kankaanranta et al, 2004,Citation56 with the permission of Respiratory Research.
Abbreviation: ICS, inhaled corticosteroids.
Figure 2 The dose-response curve of ICS.

Figure 3 Pathophysiological mechanisms involved in systemic adverse effects of ICS in COPD patients.

Abbreviation: ICS, inhaled corticosteroids.
Figure 3 Pathophysiological mechanisms involved in systemic adverse effects of ICS in COPD patients.